Ticrr-KO 基因敲除小鼠

下单100%中奖,最高可得千元京东卡
复苏/繁育服务
产品名称

Ticrr-KO 基因敲除小鼠

产品编号

S-KO-15006

品系全称

C57BL/6JCya-Ticrrem1/Cya

品系背景

C57BL/6JCya

品系编号

KOCMP-77011-Ticrr-B6J-VA

品系状态

使用本品系发表的文献需注明: Ticrr-KO 基因敲除小鼠 mice (Strain S-KO-15006) were purchased from Cyagen.
交付类型
周龄
性别
基因型
数量

基本信息

基因研究概述

质控标准

基因
基因全称
TOPBP1-interacting checkpoint and replication regulator
基因别称
5730590G19Rik,Lrrk1
染色体号
Chr 7 (Mouse)
转录本 ID
NCBI: NM_029835.1 | Ensembl: ENSMUST00000035977
修饰方式
全身性基因敲除
靶向范围
Exon 2~6
敲除长度
~9746 bp
品系说明
该品系是基于策略设计时的数据库信息制作而成,建议您在购买前查询最新的数据库和相关文献,以获取最准确的表型信息。
表型提示
MGI:1924261Mice homozygous for an ENU-induced allele are mostly hairless, with only a light patch of hair around the face and tail. Mice homozygous for a knock-out allele show embryonic lethality before implantation. In vitro outgrowth assays show that embryos fail to hatch from the zona pellucida and die after 3 days in culture, never forming blastocysts.
基因TICRR,全称为TopBP1 interacting checkpoint and replication regulator(TopBP1相互作用的检查点和复制调节因子),在DNA复制过程中发挥重要作用。TICRR与TopBP1结合,参与DNA复制的前起始复合物(pre-IC)形成,这对于维持基因组稳定性和细胞周期进程至关重要[3]。TICRR的缺失会导致细胞周期停滞、DNA复制障碍和细胞凋亡,从而影响肿瘤的发生和发展[3]。

TICRR在多种癌症中表达上调,包括肺癌、子宫内膜癌、肝细胞癌和乳头状肾细胞癌等。在肺癌中,TICRR的表达水平与肿瘤分期、性别、吸烟状况和肿瘤突变负荷(TMB)等因素相关,并且与患者预后不良有关[1,5]。在子宫内膜癌中,TICRR和PPIF基因的过表达与患者预后不良相关,并且可能成为潜在的治疗靶点[2]。在肝细胞癌中,TICRR的表达水平与肿瘤分期、预后和免疫浸润水平相关,并且可能成为潜在的诊断和预后生物标志物[6,7]。在乳头状肾细胞癌中,TICRR的表达水平与患者预后不良相关,并且可能成为潜在的治疗靶点[8]。

除了在肿瘤发生和发展中的作用,TICRR还与肩关节脱位等疾病相关。研究发现,位于TICRR基因内含子区域的rs12913965位点与肩关节脱位风险增加相关,这表明TICRR可能参与肩关节脱位的发生机制[4]。

综上所述,TICRR在DNA复制、肿瘤发生和发展、肩关节脱位等生物学过程中发挥重要作用。TICRR的表达水平与多种癌症的预后相关,并且可能成为潜在的预后生物标志物和治疗靶点。深入研究TICRR的功能和机制有助于揭示肿瘤发生和发展的分子机制,为肿瘤的诊断和治疗提供新的思路和策略。

参考文献:
1. Zheng, Xunbo, Han, Li, Guan, Jun, Liu, Mengyuan, Huang, Hanxing. 2023. TICRR serves as a prognostic biomarker in lung adenocarcinoma with implications in RNA epigenetic modification, DDR pathway, and RNA metabolism. In Frontiers in oncology, 13, 1274439. doi:10.3389/fonc.2023.1274439. https://pubmed.ncbi.nlm.nih.gov/38152367/
2. Yang, Linlin, Cui, Yunxia, Sun, Xiao, Wang, Yudong. 2021. Overexpression of TICRR and PPIF confer poor prognosis in endometrial cancer identified by gene co-expression network analysis. In Aging, 13, 4564-4589. doi:10.18632/aging.202417. https://pubmed.ncbi.nlm.nih.gov/33495413/
3. Sansam, Christopher L, Cruz, Nelly M, Danielian, Paul S, Hopkins, Nancy, Lees, Jacqueline A. . A vertebrate gene, ticrr, is an essential checkpoint and replication regulator. In Genes & development, 24, 183-94. doi:10.1101/gad.1860310. https://pubmed.ncbi.nlm.nih.gov/20080954/
4. Kim, Stuart, Kleimeyer, John P, Ahmed, Marwa A, Dragoo, Jason L, Ioannidis, John P A. 2017. [Not Available]. In International journal of sports medicine, 38, 508-514. doi:10.1055/s-0043-106190. https://pubmed.ncbi.nlm.nih.gov/28521375/
5. Zhang, Zhao, Huang, Congcong, Wu, Jun, Cheng, Quan, Wang, Shangning. . TICRR as a potential prognostic biomarker for lung adenocarcinoma: A comprehensive analysis using TCGA database. In Medicine, 103, e38660. doi:10.1097/MD.0000000000038660. https://pubmed.ncbi.nlm.nih.gov/38968480/
6. Chen, Jing-Jing, Zhang, Lu-Lu, Liu, Zhen, Chen, Fang, Shen, Jilu. 2023. Comprehensive Analysis of TICRR in Hepatocellular Carcinoma Based on Bioinformatics Analysis. In Biochemical genetics, 62, 1-17. doi:10.1007/s10528-023-10378-w. https://pubmed.ncbi.nlm.nih.gov/37266876/
7. He, Ke-Jie, Zhang, Yang-Fan, Liang, Lai-Ying, Lin, Ying, Guleng, Bayasi. 2022. ncRNAs-mediated high expression of TICRR promotes tumor cell proliferation and migration and is correlated with poor prognosis and tumor immune infiltration of hepatocellular carcinoma. In Molecular therapy. Nucleic acids, 30, 80-94. doi:10.1016/j.omtn.2022.09.007. https://pubmed.ncbi.nlm.nih.gov/36213689/
8. Xia, Shuang, Lin, Yan, Lin, Jiaqiong, Tan, Xuexian, Huang, Zena. 2021. Increased Expression of TICRR Predicts Poor Clinical Outcomes: A Potential Therapeutic Target for Papillary Renal Cell Carcinoma. In Frontiers in genetics, 11, 605378. doi:10.3389/fgene.2020.605378. https://pubmed.ncbi.nlm.nih.gov/33505430/